Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bigheadd:
Sounds like it reflects the fact that some of the restricted shares held by management are no longer restircted and are now a part of the o/s tradeable shares. Would be my guess.
Some info from their filing, gives basic info about company:
https://www.otcstockinfo.com/repository/659571/659571_FR11.pdf
Still tying to figure out at this point who sells 140,000 at $0.10 and 20,000 at $0.09??
Dwudman, that is correct for SEC registered companies, but with MFYS not being an SEC registered company (for EDGAR filing purposes at least) I am not sure they will hold to those deadlines. IMHO
Question on moving to OTC:BB
This is a real key as far as I am concerned is in getting off of the pink sheets. Does anyone know if the delay in reconciling the US accounts from the former shell company is what is keeping Medify from trying to get to the OTC:BB? To me getting audited consolidated financials that will get through the SEC filing would be the delay. What are the requirements for Bulletin board trading? I do not believe it is the same as NASDAQ (PPS and revenue requirements). Thanks.
Let's please not let this good place for common exchanges turn into something like RB.
205 persons trial in England??
Does anyone know what the result of the 205 person trial was in, I believe, Doncaster??? Have heard nothing about how that was progressing towards the 105,000 persons potential roll-out.
Would love either of them, happen to be at the point of life when we have the X-3, which we love. But if Medify will pay off I may be able to afford both the family car and a toy for me.
I'll toast to that..
Jack on the rocks.
Merry Christmas to all!!!
A lot of volume today leading into a holiday. Maybe some interest is being generated.
Ok, thanks solid for digging up the information. For me, I agree, glad there is a deal, and that we have had some good discussion today. If the monthly rate is 1/3, even at the conservative profit margin and P/E ratio, this one deal would provide support for a stock price in the mid $.30's. With it being 20,000 users, the 105,000 potential users from the current pilot going on in the UK would add 5 times that amount. The two deals alone in a 18 month time frame could lead to income that would support a pps of $1.60 to $1.90, even by conservative measures. That with additional roll-outs should be good news for those who are in long-term.
IMHO.
Thanks for everyone involved in today's discussion. It has been good dialogue.
No problem at all, toofoolish. It could be an initial licensing fee, but I cannot imagine that there is not a monthly charge component as well. Perhaps it is the initial charge of 69 euros and something along the line of 50 euros per month?? It is not that far-fetched, however, for the monthly fee to be $80. I know blackberry usage in the US, depending on what your getting in your service, can easily run $70 and even $150 per month. So $89 US money per month would not be out of the realm of possibility for this service. Especially if this is for remote access of patient records, and the efficiencies that would bring to a physician practice.
All is just my humble opinion. Nice to have something to be kicking around though, regardless.
toofoolish:
That was a point I considered. I used a monthly fee, in that is the model being followed in the UK and has been the only model Medify has discussed to date to my knowledge. Besides, I am not aware of any remote device (cell phone, Blackberry, Trio, etc.) which does not utilize a monthly charge plan. Anyway, there were assumptions made (I too hope the profit margin is low and the P/E multiple low for a development stage company), but the analysis was put out there simply to encourage conversation and discussion. Was hoping to hear varying assumptions on the subject by all. I find that of more interest personally than the consistent decline in pps and joke postings. (no personal offense oledudes, sometimes you have to laugh to keep from crying). Just hoping for some positives for all of us heading into 2006.
Estimated PPS Calculation??
69 Euro x $1.20 exchange rate = $82.80 per license per month
$82.80 x 20,000 licenses - $1,656,000 in monthly revenue
$1,656,000 x 12 months = $19,872,000 in annual revenue
$19,872,000 x 20% profit margin = $3,974,400 in net income
$3,974,400 / 80,000,000 o/s share equivalents = $0.04968 EPS
.04968 x 20 P/E multiple = $.9936 per share on contract
If they start reporting revenues quarterly, above could be one of many potential impacts. Just scenario but a conservative one.
Clancy:
At this point, further dilution in the market is a nauseating thought. Positive is that not much further to fall I guess.
I want to think I saw someone else's e-mail address at the bottom of a recently release news item (possibly the legal counsel they have now). I would hope that Trevor is concentrating on sales and marketing and not answering investor e-mails. The info is good, but should be someone else handling those inquiries. JMO
The bright-side of it is that volume trades all day were in the .20-.21 cent range and then some piddly-a$$ 360 share trade goes through at the end of the day for .16 cents which makes the end of day balances look awful.
More good news, more low priced sales at high volume. I am too tired of it to even comment any longer.
I agree Lem, good potential news. To agree with oledudes though, am afraid you won't see a movement until revenue and financials become consistently reported. News doesn't pay the bills or create EPS. But completely agree...sounds like a great step forward and foundation for things to come.
Capitain, I believe this is a Medify release. In the SEC disclosure paragraph at the bottom it speaks only about Medify Solutions. BTW, to my knowledge Medify still does not have anything on file with the SEC. At least if you search the EDGAR database, nothing shows up.
Verylong....whomever just wasted $9.99 on trade commission for a $63 trade could use some of your wisdom. Pitiful.
Let's hope for the typical government response of just throwing more money into it. The downer I saw was it delaying the more complex Medical Records portion of the project. It shouldn't have an impact on the e-learning product though.
Solid...
If they have a fiscal December year-end, then the quarter will not be over until September 30. The SEC gives 40 days after the quarter before their 10-Q filings are due, so I wouldn't expect anything until early November for 3rd Quarter. IMO
I wonder why this is not showing up as a "press release" on the financial sites? I understand the filing from last week to pink sheets not showing up, but this seems to be an actual PR. Any thoughts?
OK..thanks, bax
Does anyone know if this was the release they have alluded to providing by the end of September, or if there is another release dealing with the pilot programs to come? With their fiscal YE being December, there should be a September quarter end release coming which should be out by Nov. 9 (40 day SEC quarterly filing window).
With the filing not being a press release it is not being showed as "news" on yahoo, cnnfn, etc. Most may not even know it is out. I would not have known if not for the post.
What do you think?? Frustration with the cash and revenue situation?
Has anyone been in contact with either the administrator or Chief-of-staff of any of the facilities involved the pilot program to see if they are using medifyremote and what their satisfaction level with it has been? Thanks.
Interesting is that I see all of the the large block trades going through on Level 2 through IHUB, but my up to the minute quotes on E-trade only show a little over 900k shares having been traded all day. Strange.
Question about referenced sales targets...First time poster, daily reader, 5 month shareholder. I have read all of the releases to date, are the referenced sales targets the ones mentioned by Johnathan Bryant in the "quarterly release" from a few months back?" Those are the only ones I can recall. If anyone else has other information, I would like to hear it.
Also, does anyone know if the potential revenues after trials that have been discussed (i.e. $25 million annual amounts I have seen) will be Medify revenue or if that is a gross contractual amount before any revenue sharing with Osyris, Orange or Oracle?
If it is a 50/50 split, that would be $12.5 million in revenue to Medify, $3.75 million to the bottom-line (assuming 30% margin), which is an EPS of $.045 (assuming 80 million in stock). A conservative PE of 20 times earnings would put us at a PPS of $0.90. Seems undervalued, and at my current basis I hope I am right. Thanks for the contributions guys.
My understanding is that pink sheets companies, since they are not regulated by the SEC do not have to report scheduled earnings. But I could be wrong.